Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T12:56:03.810Z.
Consensus retrieved: 2026-10-06T10:07:15.695Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T12:56:03.810Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4f13a1340446ed9d2fab2f71bf594eb69a7c02e94fe434461414907d992f5ed7
Forward PE Ratio (N/A) = Dated Quote Price ($16.04) / Consensus Forward EPS ($-3.17)
FORWARD PE RATIO
N/A
Cullinan Therapeutics, Inc.
Market Cap
$985.79M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | $985.79M | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $989.05M | N/A |
| CeriBell, Inc. (CBLL)vs › | $943.26M | N/A |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.03B | 5.45 |
| Immatics N.V. (IMTX)vs › | $1.04B | N/A |
| Arbutus Biopharma Corp (ABUS)vs › | $922.50M | 6.31 |
| HealthStream, Inc. (HSTM)vs › | $921.45M | 42.74 |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | N/A |
| Bioventus Inc. (BVS)vs › | $915.95M | 17.36 |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $903.13M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $16.04, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-3.17 | $-3.64 – $-2.79 | 8 | n/m |
| 2027-12-31 | $-2.50 | $-3.50 – $-1.57 | 8 | n/m |
| 2028-12-31 | $-3.05 | $-3.40 – $-2.83 | 7 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
